Consistent with previous studies [4], [5], serum levels of A-FABP in our type 2 diabetic patients were independently associated with lipid and parameters of adiposity such as TG, LDL-c and BMI, especially after the 48-week rosiglitazone treatment. The gene discussed is FABP4; the disease is type 2 diabetes mellitus.